HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
about
Low High-Density Lipoprotein and Risk of Myocardial InfarctionHigh density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular riskHDL in sepsis - risk factor and therapeutic approachVasculoprotection as a Convergent, Multi-Targeted Mechanism of Anti-AD Therapeutics and InterventionsAdvances in the Study of the Antiatherogenic Function and Novel Therapies for HDLA new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretionHDL and glucose metabolism: current evidence and therapeutic potentialAutoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunityThe interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipidsRegular-Fat Dairy and Human Health: A Synopsis of Symposia Presented in Europe and North America (2014-2015)High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung DiseaseHigh-Density Lipoproteins: Nature's Multifunctional Nanoparticles3-nitrotyrosine modified proteins in atherosclerosisAmyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosisHDL-apoA-I exchange: rapid detection and association with atherosclerosisAdd-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatinA high throughput biochemical fluorometric method for measuring lipid peroxidation in HDLEpidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.Mapping and Congenic Dissection of Genetic Loci Contributing to Hyperglycemia and Dyslipidemia in Mice.Ligand-Free Fe3 O4 /CMCS Nanoclusters with Negative Charges for Efficient Structure-Selective Protein Adsorption.Perspectives and opportunities for nanomedicine in the management of atherosclerosis.Evaluating the relationship between biomarkers of potential harm and biomarkers of tobacco exposure among current, past, and nonsmokers: data from the National Health and Nutrition Examination Survey 2007-2012.Tangier disease: epidemiology, pathophysiology, and management.Inverse relationship between apolipoprotein A-I and cerebral white matter lesions: a cross-sectional study in middle-aged and elderly subjects.HDL anti-oxidant function associates with LDL level in young adults.Immunochemical Approach for Monitoring of Structural Transition of ApoA-I upon HDL Formation Using Novel Monoclonal AntibodiesA plant-based diet and heart failure: case report and literature reviewEarly onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.Reduced HDL function in children and young adults with type 1 diabetes.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Apolipoprotein A-I attenuates palmitate-mediated NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid raftsHIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexinATP-binding cassette transporter 1 attenuates ovalbumin-induced neutrophilic airway inflammation.Identification of small proline-rich repeat protein 3 as a novel atheroprotective factor that promotes adaptive Akt signaling in vascular smooth muscle cells.Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesityHuman HDL containing a novel apoC-I isoform induces smooth muscle cell apoptosis.Expression, purification and reconstitution of the C-terminal transmembrane domain of scavenger receptor BI into detergent micelles for NMR analysis.Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels.Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.P2Y13 receptor regulates HDL metabolism and atherosclerosis in vivo
P2860
Q26773899-78676B26-BCD7-4484-9A12-5707921A4DB4Q26775420-68C4E181-CC93-4875-A31C-A5753050932AQ26777964-F19BEF6D-33A2-44F8-8CB6-51AF58ECFE18Q26781557-847598DF-3FA0-423E-9AAD-748B3194FF2EQ26801507-78BFF47E-AF46-48E8-B8C7-57456F1B639DQ26865600-9113395C-FC9E-48DF-8A0C-20CFA59EC91FQ26996502-DBB4F282-BF8A-499B-A27B-2FED77804C54Q27004493-F35260C7-6BE0-4918-BFB8-9378D69EA7F2Q27025329-56D6AA62-7C52-43FD-A494-1D758F8BCBD2Q28066150-052C7246-04CD-43D1-B70A-4B1EFF7E41D1Q28075541-32640624-26E8-4E6A-9219-C275338EBD1BQ28077290-AA88DB3C-C499-4E2B-9272-CF7FBD5D10C4Q28083260-234B0E80-8D97-401A-97BA-12EF258AD1F3Q28116206-74A60CFE-81ED-4AD3-9DAD-38F523696201Q28535779-7AC0EF6A-75A1-45E6-B6EC-8DDC7FAE2300Q28538633-646044ED-F672-4BFD-886B-EF54F1E3B0C7Q28544713-2545BD9B-0181-4334-8957-EB82C70594B1Q30251632-9144CC40-7421-4441-895D-6B72D3137940Q30277373-9710E65E-B53C-4350-AFDB-E958AD4EF2F4Q30385215-6CA6E435-F855-4C72-8FD0-B5E3063EF12BQ30455490-2C831A6F-9F6D-4619-9BC6-993C685C568AQ31109084-C32EBBC4-9E24-450B-AD87-6CE7F5951C9DQ33402921-AD2C30BF-8A36-4B85-BFBB-762B76631B8AQ33599314-0414CDEF-E7B0-417C-B9EC-9705A6DE6A9EQ33689682-70C61713-839A-4C10-87C4-29C594F07F87Q33774419-A37C7797-D8AB-4A3E-BFCC-64E7159A9679Q33785595-7F311E9C-BA0D-4CFE-8A50-11C61D68E266Q33828570-B2771BEA-34DA-416C-BE66-EB18A08AC6C3Q33882594-62D9F9EA-7381-4A38-A22A-C4BE2F9BA4F6Q33972551-FF4B4891-B3A9-478F-8AB9-66F0B831EC0EQ34221770-0FCE70C8-F9DD-4944-911D-A6032E6FA61EQ34355599-6D8AD4B6-A86C-4A19-A850-9FBFA9A508AFQ34471217-9A3A64E3-2918-424D-977B-58B57FD589CBQ34550490-FF09AA00-74DB-4E25-9A30-8F6061A4DD06Q34563341-896293F7-CC07-4C2E-A2D4-3E04D03D4812Q34564734-06092E8C-F62D-47EB-AC54-3A3A6EFA0B3EQ34734451-B1CA90FE-A730-4C6A-8D40-7E899A17B208Q34851822-41C6912D-FC5F-4529-A459-8B43B58CE89FQ35051225-01DCC5F5-0FCA-4461-9AB5-100B7501FD48Q35158162-C3916D29-4F7F-4CB4-B5B6-6AE69198BD04
P2860
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
@en
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
@nl
type
label
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
@en
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
@nl
prefLabel
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
@en
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
@nl
P2093
P2860
P1476
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
@en
P2093
Alan M Fogelman
Brian J Van Lenten
Mohamad Navab
Srinivasa T Reddy
P2860
P304
P356
10.1038/NRCARDIO.2010.222
P407
P577
2011-02-08T00:00:00Z